PL2993186T3 - Przeciwciało monoklonalne i sposób jego otrzymywania - Google Patents

Przeciwciało monoklonalne i sposób jego otrzymywania

Info

Publication number: PL2993186T3
Authority: PL; Poland
Prior art keywords: monoclonal antibody; monoclonal; antibody
Prior art date: 2008-03-14

Application number

PL15171431T

Other languages

English (en)

Inventor

Ramakrishnan Melarkode

Pradip Nair

Sundaraj David Rajkumar

Kedarnath Nanjund Sastry

Monalisa Chatterji

Laxmi Adhikary

Hema Balasubramanian

Jose Enrique Montero Casimiro

Josefa Lombardero Valladares

Rolando Perez Rodriguez

Original Assignee

Biocon Limited

Centro De Inmunologia Molecular

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-14

Filing date

2008-09-04

Publication date

2020-02-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2993186(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-09-04 Application filed by Biocon Limited, Centro De Inmunologia Molecular filed Critical Biocon Limited

2020-02-28 Publication of PL2993186T3 publication Critical patent/PL2993186T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL15171431T 2008-03-14 2008-09-04 Przeciwciało monoklonalne i sposób jego otrzymywania PL2993186T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
IN650CH2008		2008-03-14
EP15171431.8A EP2993186B1 (en)	2008-03-14	2008-09-04	A monoclonal antibody and a method thereof
EP08873217A EP2265644A4 (en)	2008-03-14	2008-09-04	MONOCLONAL ANTIBODY AND CORRESPONDING METHOD
PCT/IN2008/000562 WO2009113083A1 (en)	2008-03-14	2008-09-04	A monoclonal antibody and a method thereof

Publications (1)

Publication Number	Publication Date
PL2993186T3 true PL2993186T3 (pl)	2020-02-28

Family

ID=41064805

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15171431T PL2993186T3 (pl)	2008-03-14	2008-09-04	Przeciwciało monoklonalne i sposób jego otrzymywania

Country Status (26)

Country	Link
US (7)	US8524233B2 (pl)
EP (2)	EP2993186B1 (pl)
JP (3)	JP2011513479A (pl)
KR (1)	KR20100126811A (pl)
CN (1)	CN101970493A (pl)
AR (1)	AR072247A1 (pl)
AU (1)	AU2008352540B2 (pl)
BR (1)	BRPI0822447A2 (pl)
CA (1)	CA2716919C (pl)
CL (1)	CL2009000618A1 (pl)
CO (1)	CO6331445A2 (pl)
DK (1)	DK2993186T3 (pl)
EA (1)	EA201001467A1 (pl)
ES (1)	ES2759075T3 (pl)
HK (1)	HK1223941A1 (pl)
IL (1)	IL207917A0 (pl)
MX (1)	MX2010010085A (pl)
MY (1)	MY159517A (pl)
NZ (1)	NZ587632A (pl)
PL (1)	PL2993186T3 (pl)
PT (1)	PT2993186T (pl)
TW (1)	TWI485160B (pl)
UA (1)	UA104587C2 (pl)
UY (1)	UY31710A (pl)
WO (1)	WO2009113083A1 (pl)
ZA (1)	ZA201005843B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2119453E (pt) *	2006-12-26	2015-09-01	Ct De Inmunolgã A Molecular	Composições farmacêuticas capazes de induzir apoptose em células tumorais, úteis para o diagnóstico e o tratamento da leucemia linfocítica crónica de células
EA201001467A1 (ru)	2008-03-14	2011-06-30	Биокон Лимитед	Моноклональное антитело и способ его использования
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
CN104531812A (zh)	2010-10-01	2015-04-22	现代治疗公司	设计核酸及其使用方法
US8710200B2 (en)	2011-03-31	2014-04-29	Moderna Therapeutics, Inc.	Engineered nucleic acids encoding a modified erythropoietin and their expression
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
HUE057725T2 (hu)	2011-10-03	2022-06-28	Modernatx Inc	Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
LT2791160T (lt)	2011-12-16	2022-06-10	Modernatx, Inc.	Modifikuotos mrnr sudėtys
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
AU2013243954A1 (en)	2012-04-02	2014-10-30	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt)	2012-11-26	2022-06-28	Modernatx Inc	Arn modificado nas porções terminais
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
WO2015011660A1 (en) *	2013-07-23	2015-01-29	Biocon Limited	Methods for controlling fucosylation levels in proteins
DK3024485T3 (da)	2013-07-23	2020-12-07	Biocon Ltd	Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
EP3052106A4 (en)	2013-09-30	2017-07-19	ModernaTX, Inc.	Polynucleotides encoding immune modulating polypeptides
AU2014329452B2 (en)	2013-10-03	2019-06-20	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
CN104497141B (zh) *	2014-12-31	2017-10-10	百泰生物药业有限公司	抗人cd6分子的治疗性抗体
JP6930916B2 (ja) *	2015-02-12	2021-09-01	ユニヴァーシティオブサザンカリフォルニアＵｎｉｖｅｒｓｉｔｙｏｆＳｏｕｔｈｅｒｎＣａｌｉｆｏｒｎｉａ	疾患予防および治療における成長ホルモン受容体の遮断剤
US10562975B2 (en)	2016-06-15	2020-02-18	The Regents Of The University Of Michigan	CD6 antibody for treatment of T-cell mediated diseases or disorders
EP3528846A4 (en) *	2016-10-18	2020-06-03	Biocon Limited	USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
PL3529274T3 (pl) *	2016-10-21	2024-09-09	Biocon Limited	Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
CN108178797B (zh) *	2017-12-29	2020-12-01	西南大学	一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
EP3759140A1 (en)	2018-02-27	2021-01-06	Equillium, Inc.	Anti cd6 antibodies for treating severe asthma
JP7376564B2 (ja) *	2018-06-29	2023-11-08	シティ・オブ・ホープ	特定の自己免疫疾患を治療するためのｃｄ６標的キメラ抗原受容体
CN113490511B (zh) *	2019-02-26	2024-07-09	伊奎利厄姆股份有限公司	用于治疗狼疮的抗cd6抗体组合物和方法
WO2020232247A1 (en)	2019-05-14	2020-11-19	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
US20230151107A1 (en) *	2020-04-04	2023-05-18	Biocon Limited	Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
US12006366B2 (en)	2020-06-11	2024-06-11	Provention Bio, Inc.	Methods and compositions for preventing type 1 diabetes
AU2022344418A1 (en)	2021-09-08	2024-04-04	Centro De Inmunologia Molecular	Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper- inflammatory response

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US699755A (en)	1902-03-06	1902-05-13	Ira G Hoag	Train-order box in connection with semaphores.
US6162432A (en)	1991-10-07	2000-12-19	Biogen, Inc.	Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en)	1993-06-03	1995-01-04	Mitsubishi Chemical Corporation	Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5998172A (en)	1993-11-02	1999-12-07	Duke University	Anti-CD6 ligand antibodies
JPH09508784A (ja)	1993-11-02	1997-09-09	デュークユニヴァーシティー	Ｃｄ６リガンド
CU22615A1 (es) *	1994-06-30	2000-02-10	Centro Inmunologia Molecular	Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ES2435462T3 (es)	1995-07-27	2013-12-19	Genentech, Inc.	Formulación de proteína liofilizada isotónica estable
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
CU22584A1 (es) *	1995-11-17	1999-11-03	Centro Inmunologia Molecular	Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
BR9708231A (pt)	1996-03-20	1999-08-03	Hoechst Marion Roussel Inc	Compostos tricíclicos que têm uma atividade face a integrinas principalmente face à integrina alfavbeta3 seu processo de preparação e os intermediários desse processo sua aplicação a título de medicamentos e composiçóes farmacêuticas que os contêm
EP0977991A4 (en) *	1997-03-03	2004-12-15	Bristol Myers Squibb Co	MONOCLONAL ANTIBODIES FOR HUMAN CD6
WO1998047531A2 (en) *	1997-04-21	1998-10-29	Arch Development Corporation	Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) *	1999-03-26	2000-10-05	Human Genome Sciences, Inc.	Neutrokine-alpha binding proteins and methods based thereon
DK1176981T3 (da)	1999-05-07	2006-04-10	Genentech Inc	Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
EP1263960A2 (en) *	2000-03-16	2002-12-11	Genentech, Inc.	Anti-tissue factor antibodies with enhanced anticoagulant potency
WO2001091793A1 (en)	2000-05-26	2001-12-06	Smithkline Beecham Corporation	Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
ES2192128B1 (es)	2001-04-27	2005-01-01	Universidad De Vigo	Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
AU2002324556A1 (en)	2001-07-25	2003-02-17	Protein Design Labs, Inc.	Stable lyophilized pharmaceutical formulation of igg antibodies
WO2004019861A2 (en)	2002-08-28	2004-03-11	Pharmacia Corporation	Stable ph optimized formulation of a modified antibody
EP1460088A1 (en) *	2003-03-21	2004-09-22	Biotest AG	Humanized anti-CD4 antibody with immunosuppressive properties
NZ542964A (en)	2003-04-04	2008-06-30	Novartis Ag	Stable, highly concentrated liquid formulations, which are particularly suitable for subcutaneous administration
DE602005018325D1 (de) *	2004-02-19	2010-01-28	Genentech Inc	Antikörper mit korrigierten cdr
KR101266716B1 (ko)	2004-06-03	2013-05-31	노비뮨 에스 에이	항-ｃｄ3 항체 및 그의 사용 방법
EP2325206B1 (en)	2004-11-12	2014-03-19	Xencor, Inc.	Fc variants with altered binding to fcrn
DOP2006000022A (es)	2005-01-28	2006-08-15	Wyeth Corp	Formulaciones líquidas estabilizadas de polipetidos
WO2007142667A2 (en)	2005-10-13	2007-12-13	Human Genome Sciences, Inc.	Treatment of patients with autoantibody positive disease
KR20090021298A (ko)	2006-06-14	2009-03-02	임클론 시스템즈 인코포레이티드	항-ｅｇｆｒ 항체의 동결건조 제제
WO2008071394A1 (en)	2006-12-11	2008-06-19	F. Hoffmann-La Roche Ag	Abeta antibody parenteral formulation
CN101199483B (zh)	2006-12-14	2011-01-26	上海中信国健药业股份有限公司	一种稳定的抗her2人源化抗体制剂
EP2119452B1 (en)	2006-12-26	2020-03-04	Centro de Inmunologia Molecular	Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
PT2119453E (pt)	2006-12-26	2015-09-01	Ct De Inmunolgã A Molecular	Composições farmacêuticas capazes de induzir apoptose em células tumorais, úteis para o diagnóstico e o tratamento da leucemia linfocítica crónica de células
PE20081610A1 (es)	2007-01-09	2008-12-09	Wyeth Corp	Formulaciones de anticuerpos anti-il-13 y usos de los mismos
WO2008106134A2 (en)	2007-02-28	2008-09-04	Schering Corporation	Engineered anti-il-23r antibodies
US20090208492A1 (en)	2007-06-14	2009-08-20	Elan Pharmaceuticals, Inc.	Lyophilized Immunoglobulin Formulations and Methods of Preparation
US7951368B2 (en)	2007-06-25	2011-05-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en)	2007-09-21	2009-03-26	F. Hoffmann-La Roche Ag	Pharmaceutical formulation for il-ir antibody
EA201001467A1 (ru)	2008-03-14	2011-06-30	Биокон Лимитед	Моноклональное антитело и способ его использования
CA2742969A1 (en)	2008-11-07	2010-05-14	Fabrus Llc	Anti-dll4 antibodies and uses thereof
MX2012005863A (es)	2009-11-20	2013-01-18	Centro Inmunologia Molecular	Formulaciones de anticuerpos.
CN102559636B (zh)	2011-12-30	2014-03-12	百泰生物药业有限公司	用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
DK3024485T3 (da)	2013-07-23	2020-12-07	Biocon Ltd	Anvendelse af en CD6-bindingspartner og fremgangsmåde baseret derpå
WO2015011660A1 (en)	2013-07-23	2015-01-29	Biocon Limited	Methods for controlling fucosylation levels in proteins
US10562975B2 (en)	2016-06-15	2020-02-18	The Regents Of The University Of Michigan	CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2018024896A1 (en)	2016-08-05	2018-02-08	INSERM (Institut National de la Santé et de la Recherche Médicale)	EX VIVO GENERATION OF γδ FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF
EP3528846A4 (en)	2016-10-18	2020-06-03	Biocon Limited	USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
PL3529274T3 (pl)	2016-10-21	2024-09-09	Biocon Limited	Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
EP3759140A1 (en)	2018-02-27	2021-01-06	Equillium, Inc.	Anti cd6 antibodies for treating severe asthma
CN113490511B (zh)	2019-02-26	2024-07-09	伊奎利厄姆股份有限公司	用于治疗狼疮的抗cd6抗体组合物和方法
US20230151107A1 (en)	2020-04-04	2023-05-18	Biocon Limited	Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
MX2023006595A (es)	2020-12-04	2023-08-11	Equillium Inc	Metodos para dirigir selectivamente celulas con cd6alto y para disminuir la actividad de linfocitos tef.

2008
- 2008-09-04 EA EA201001467A patent/EA201001467A1/ru unknown
- 2008-09-04 MY MYPI2010003599A patent/MY159517A/en unknown
- 2008-09-04 EP EP15171431.8A patent/EP2993186B1/en active Active
- 2008-09-04 PT PT151714318T patent/PT2993186T/pt unknown
- 2008-09-04 MX MX2010010085A patent/MX2010010085A/es active IP Right Grant
- 2008-09-04 BR BRPI0822447-1A patent/BRPI0822447A2/pt not_active Application Discontinuation
- 2008-09-04 EP EP08873217A patent/EP2265644A4/en not_active Ceased
- 2008-09-04 UA UAA201010915A patent/UA104587C2/ru unknown
- 2008-09-04 DK DK15171431T patent/DK2993186T3/da active
- 2008-09-04 AU AU2008352540A patent/AU2008352540B2/en active Active
- 2008-09-04 JP JP2010550331A patent/JP2011513479A/ja not_active Withdrawn
- 2008-09-04 PL PL15171431T patent/PL2993186T3/pl unknown
- 2008-09-04 US US12/921,544 patent/US8524233B2/en active Active
- 2008-09-04 CA CA2716919A patent/CA2716919C/en active Active
- 2008-09-04 WO PCT/IN2008/000562 patent/WO2009113083A1/en active Application Filing
- 2008-09-04 NZ NZ587632A patent/NZ587632A/en unknown
- 2008-09-04 ES ES15171431T patent/ES2759075T3/es active Active
- 2008-09-04 CN CN2008801277438A patent/CN101970493A/zh active Pending
- 2008-09-04 KR KR1020107023041A patent/KR20100126811A/ko not_active Ceased
2009
- 2009-03-13 TW TW098108279A patent/TWI485160B/zh active
- 2009-03-13 CL CL2009000618A patent/CL2009000618A1/es unknown
- 2009-03-13 UY UY0001031710A patent/UY31710A/es not_active Application Discontinuation
- 2009-03-13 AR ARP090100903A patent/AR072247A1/es unknown
2010
- 2010-08-16 ZA ZA2010/05843A patent/ZA201005843B/en unknown
- 2010-09-01 IL IL207917A patent/IL207917A0/en active IP Right Grant
- 2010-09-13 CO CO10113068A patent/CO6331445A2/es not_active Application Discontinuation
2011
- 2011-06-23 HK HK16110095.5A patent/HK1223941A1/zh unknown
2013
- 2013-09-03 US US14/016,318 patent/US9217037B2/en active Active
- 2013-11-01 JP JP2013228779A patent/JP2014065711A/ja not_active Withdrawn
2014
- 2014-03-07 JP JP2014045020A patent/JP5856209B2/ja active Active
2015
- 2015-12-15 US US14/969,461 patent/US9670285B2/en active Active
2017
- 2017-05-31 US US15/609,625 patent/US10000573B2/en active Active
2018
- 2018-05-09 US US15/975,681 patent/US10669346B2/en active Active
2020
- 2020-04-29 US US16/862,417 patent/US11981743B2/en active Active
2024
- 2024-04-09 US US18/630,519 patent/US20240417483A1/en active Pending

Also Published As

Publication number	Publication date
EP2265644A4 (en)	2011-04-27
US20180258179A1 (en)	2018-09-13
HK1223941A1 (zh)	2017-08-11
AU2008352540B2 (en)	2012-06-28
KR20100126811A (ko)	2010-12-02
US9670285B2 (en)	2017-06-06
BRPI0822447A2 (pt)	2015-06-16
ZA201005843B (en)	2011-04-28
CO6331445A2 (es)	2011-10-20
US20240417483A1 (en)	2024-12-19
US20110002939A1 (en)	2011-01-06
UY31710A (es)	2009-11-10
AU2008352540A1 (en)	2009-09-17
EP2265644A1 (en)	2010-12-29
CN101970493A (zh)	2011-02-09
JP2011513479A (ja)	2011-04-28
TW201000125A (en)	2010-01-01
IL207917A0 (en)	2010-12-30
JP2014065711A (ja)	2014-04-17
CL2009000618A1 (es)	2011-05-27
US20140031529A1 (en)	2014-01-30
CA2716919A1 (en)	2009-09-17
US20160168256A1 (en)	2016-06-16
WO2009113083A1 (en)	2009-09-17
EP2993186A1 (en)	2016-03-09
DK2993186T3 (da)	2019-11-25
JP2014159425A (ja)	2014-09-04
TWI485160B (zh)	2015-05-21
PT2993186T (pt)	2019-11-29
ES2759075T3 (es)	2020-05-07
EA201001467A1 (ru)	2011-06-30
US20210122829A1 (en)	2021-04-29
US8524233B2 (en)	2013-09-03
US10000573B2 (en)	2018-06-19
JP5856209B2 (ja)	2016-02-09
UA104587C2 (ru)	2014-02-25
US20170281808A1 (en)	2017-10-05
MX2010010085A (es)	2011-03-29
CA2716919C (en)	2015-01-20
AR072247A1 (es)	2010-08-18
US11981743B2 (en)	2024-05-14
NZ587632A (en)	2012-06-29
EP2993186B1 (en)	2019-09-04
MY159517A (en)	2017-01-13
US10669346B2 (en)	2020-06-02
US9217037B2 (en)	2015-12-22

Publication	Publication Date	Title
HK1223941A1 (zh)	2017-08-11	單克隆抗體及其方法
SG10201601279SA (en)	2016-03-30	Monoclonal Antibody STRO-4
EP2331579A4 (en)	2013-01-23	MONOCLONAL ANTIBODIES
IL201082A0 (en)	2010-05-17	Bispecific antibodies and methods for production thereof
EP2021373A4 (en)	2010-06-02	MONOCLONAL ANTIBODY VCAM-1 SPECIFIC
HK1194395A1 (zh)	2014-10-17	抗體及其製備和使用方法
EP2374883A4 (en)	2013-01-16	ANTI-CD4 ANTIBODIES
ZA200809662B (en)	2014-05-28	Modified humanised anti-interleukin-18 antibodies
IL207217A0 (en)	2010-12-30	Humanized anti-c5ar antibodies
PT2510011E (pt)	2014-12-12	Anticorpos monoclonais que se ligam a b7h6 e suas utilizações
ZA201207484B (en)	2013-06-26	Humanized anti-egfl7 antibodies and methods using same
IL204835A0 (en)	2010-11-30	Humanized antibody
IL192419A0 (en)	2011-08-01	Anti-ephb4 antibodies and methods using same
IL200168A0 (en)	2010-04-15	Monoclonal anti-cxcl13 antibodies
IL231891A (en)	2016-10-31	Anti-ephrinb2 antibodies and methods for their use
SI2094728T1 (sl)	2013-06-28	Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
HK1158977A1 (zh)	2012-07-27	抗膜鐵轉運蛋白單克隆抗體及其用途
ZA200806053B (en)	2009-12-30	Anti-EphB4 antibodies and methods using same
GB0804687D0 (en)	2008-04-16	Humanized antibody
GB0804686D0 (en)	2008-04-16	Humanized antibody
GB0804684D0 (en)	2008-04-16	Humanized antibody
GB0706965D0 (en)	2007-05-16	Humanized antibody
GB0706964D0 (en)	2007-05-16	Humanized antibody
GB0706963D0 (en)	2007-05-16	Humanized antibody